Abstract
Background Persistent radiological lung abnormalities are evident in many survivors of acute coronavirus disease 2019 (COVID-19). Consolidation and ground glass opacities are interpreted to indicate subacute inflammation whereas reticulation is thought to reflect fibrosis. We sought to identify differences at molecular and cellular level, in the local immunopathology of post-COVID inflammation and fibrosis.
Methods We compared single-cell transcriptomic profiles and T cell receptor (TCR) repertoires of bronchoalveolar cells obtained from convalescent individuals with each radiological pattern, targeting lung segments affected by the predominant abnormality.
Results Single-cell transcriptomes of inflammatory and fibrotic post-COVID lung disease closely resembled each other across all cell types. However, CD4 central memory T cells and CD8 effector memory T cells were significantly more abundant in those with inflammatory radiology. Clustering of similar TCRs from multiple donors was a striking feature of both phenotypes, consistent with tissue localised antigen-specific immune responses. There was no enrichment for known SARS-CoV-2-reactive TCRs, raising the possibility of T cell-mediated immunopathology driven by failure in immune self-tolerance.
Conclusions We found no evidence that post-COVID radiographic inflammation and fibrosis are associated with differential immmunopathological pathways. Both show evidence of shared antigen-specific T cell responses, suggesting a role for therapies targeting T cells in limiting post-COVID lung damage.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
PM is supported by a Medical Research Council (MRC)/GlaxoSmithKline Experimental Medicine Initiative to Explore New Therapies network (EMINENT) Clinical Research Training Fellowship. EKD is supported by Breathing Matters. MZN is supported by a UK MRC Clinician Scientist Fellowship (MR/W00111X/1) and a Rutherford Fund Fellowship allocated by the MRC UK Regenerative Medicine Platform 2 (MR/5005579/1). MN is supported by the Wellcome Trust (207511/Z/17/Z). GST is supported by a UK MRC Clinician Scientist Fellowship (MR/N007727/1). PM, EKD, MP, JSB, MZN, MN, RCC, JCP and GST are also supported by NIHR Biomedical Research Funding to UCL and UCLH.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was approved by a UK Research Ethics Committee (North London Research Ethics Committee, reference 13/LO/0900). Written informed consent was obtained from all participants.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Discussion text and author list updated; Figures 1-3 and Supplementary Figure 1 revised.
Data Availability
scRNAseq and scTCRseq data will be available in the Gene Expression Omnibus (GEO) database at the time of peer-reviewed publication of the manuscript.
